|
Mr. McCutchen is Vice President, Business Development of Cardium Therapeutics and was appointed Vice President, Business Development of Tissue Repair Company following Cardium’s acquisition of the company in August 2006. Prior to the acquisition, Mr. McCutchen served as Vice President and Chief Financial Officer of the Tissue Repair Company. Mr. McCutchen has over 15 years of financial and business management experience in the life sciences industry. Mr. McCutchen joined Selective Genetics (formerly Prizm Pharmaceuticals) in 1993 and has been Vice President and CFO since 1994. Heading up Selective Genetics’ financial activities he has overseen 7 rounds of venture and private financings totaling more than $60 million. He also managed the spinning out of non-core technology to form a new venture backed company as well as the merger forming Selective Genetics. He has been involved in multiple corporate partnering transactions with companies such as Chiron and Biomet. Prior to joining Selective Genetics, Mr. McCutchen held various finance positions, the most recent of which was with Viagene, Inc., one of the first gene therapy biotechnology companies acquired by Chiron Corporation. He started his finance career in the investment banking industry where he was engaged in equity and debt transactions for high technology and life science companies. Mr. McCutchen received his B.A. in psychology with pre-medical sciences from Wheaton College and M.B.A. from the University of Washington, with a concentration in finance. | 